Member Info for LSBM

Thanks for sharing that video and all for your insights. I stand corrected and am invested.

MTL’s operations provide robust cash flow, but the scale of required project investment in La India and Dupax will require the company to supplement profits and cash reserves with additional fundraising—potentially debt, equity, or structured finance—to deliver full production on both projects. The company is in a strong position to contribute a meaningful portion from profits, but the funding requirement is well above normal annual earnings.

Metals Exploration PLC (MTL) posted strong operating profits in 2024 with an operational profit of US$53.5 million and pre-tax profit of US$34.6 million, driven by gold production and high gold prices. The company generated US$96.7 million in operational cash in 2024 and recorded a record pre-tax free cash flow of US$47.2 million for Q2 2025, plus cash holdings of US$43.5 million as of June 2025.

In terms of project funding requirements:

• La India project: Initial capex estimated at US$116–122 million.

• Dupax project: Capex for full development and plant conversion is currently estimated at around US$60 million (according to recent analyst assumptions), with final numbers to be confirmed after feasibility work.

Funding vs. Profit Summary

• Annual operating profit (~US$50-55 million) is substantial, but not enough to single-handedly fund both La India and Dupax developments out of internal cash flow within a one-year window.

• Required capex for new projects (La India + Dupax ≈ US$180 million) exceeds a single year’s profit by more than 3x–4x.

• The current cash position (US$43.5 million) is not sufficient for either project’s full build, but strong cash generation (about US$20–45 million per quarter) provides solid support for co-funding with new external capital.

Sharing another poster's link here, because the future looks bright: Https://www.mining.com/ubs-lifts-2026-gold-forecasts-on-us-macro-risks/

Partnering with a major player like Myriad Genetics—known for its reach in molecular diagnostics—positions Angle’s Parsortix technology for broader adoption and deeper penetration into the clinical and research oncology space. Angle has been moving its business model toward larger-scale collaborations with pharmaceutical and diagnostics leaders, which can help accelerate both adoption and validation of its liquid biopsy solutions for cancer.

Such collaborations can result in:

• Increased revenue from service agreements, technology licensing, or co-development deals.

• Enhanced credibility and validation through association with industry leaders, potentially leading to follow-on agreements and a stronger sales pipeline.

• Strategic leverage in precision oncology and companion diagnostics, with Myriad’s distribution and sales channel opening up access to wider clinical trial networks and potentially, routine clinical use

Apologies, I think the 26p options lapsed in 2024 hence the new lot at 30p.

Before then were also getting close to the directors' share options at an exercise price of 0.26.

The last time we saw this sort of gain was the day the licence for the 737 was announced. I guess the real test is to see whether this holds.

I'm getting the feeling something may be incoming. This level of trades and volume for the first 2 and a half hours of trading seems unusual for SAR. Or perhaps the AI collaboration accelerating the development of advanced neuroinflammatory treatments is well-received by the market and still filtering through.

Given the current production of ~85,000 oz/year and probable reserves of ~518,000 oz, the baseline mine life is ~6 years. New high-grade intersections combined with inferred and underground resources likely add additional ounces. This could plausibly extend mine life by 2-4 years, depending on the final resource conversion and mining method adopted. The final precise mine life extension will be confirmed after updated resource estimates and mine plan studies are completed by the end of 2025, but early drill results are promising for a meaningful extension beyond the current mine life plan.

Rough Valuation Impact:

• Using Segilola’s NPV per ounce baseline of $310 million / 518,000 oz ≈ $598 per ounce.

• An additional 170,000 to 340,000 oz could translate to an added NPV of ~$100 million to $200 million (assuming similar economics).

• Adding to current market capitalisation and net cash, this could represent a 33%-66% potential increase in underlying asset value.

The excitement is building. But please DYOR

Peer-reviewed journals are notorious for their lengthy publication processes, but SP would have had approval to say it would be soon, from which it should take 6-8 weeks. It could be any day now. I think this is an important catalyst, and excited to see this land.

Https://www.youtube.com/watch?v=PyI3GPJu0uw

Over half a million worth shares just bought.

I think a solid update in September will help, as long as the market doesn't overreact negatively to anything less than 40% gains from the past. I agree a bounce upwards is on the cards. W7L is a well-run business with opportunities for expansion in fixtures and outlets. I'm keen to hear how they will grow BA portfolio to deepen their presence across aisles.

Hopkirk, seems like the same work published and peer-reviewed https://www.cell.com/iscience/fulltext/S2589-0042(24)01200-8. However, does beg the question of why it's been submitted for review and comments again.

Summary of Naked Wines:

• Subscription model linking wine “angels” (customers) with independent winemakers to fund production.

• Extensive presence and strong performance in the US market, unlike Virgin Wines that focuses on UK/Ireland.

• Recent revenue down 8.9% with stabilising trends after bigger falls.

• Active members down about 10% but revenue per member is increasing due to order frequency and value.

• Management focused on inventory optimisation to streamline cash flow.

• Net cash improving; the company is conducting performance reviews to maximise shareholder value.

• Strong strategic initiatives and KPI improvements noted by the new CEO.

Overall, with the US market it seems they are in recovery mode.

The toxicology results must appear favourable to support Sareum’s strategic investment in AI-driven drug discovery and dual inhibitor development. This JV will not only confirm safety for Phase II trials, improve drug candidates through AI, provide deeper insight into dual inhibition mechanisms, and advance treatments for autoimmune and neuroinflammatory conditions.

Does not mean news is not brewing or incoming. We don't know when.

I think this may be the renewal of the large US health plan contract signed in early 2024, which was intended to run up to 21 months, indicating a potential renewal or extension discussion likely in mid to late 2025. J&J contract was signed early this year, so perhaps early in the pharma world for renewal discussions. Unless this is a TO situation. Stockopedia analyst forecast for this 24p.

Not sure whether you have seen these new videos. It seems the video on Method C has been improved. I certainly didn't see videos for Method A&B at the announcement. https://quantumblockchaintechnologies.co.uk/products-services c

A question I have is whether all 3 methods can be stacked? Why wouldn't whoever is interested want a 13% + 30% efficiency?

Well, what are the chances that Bitmain are one of the parties in conversation?